Prolonged bioluminescence imaging in living cells and mice using novel pro-substrates for Renilla luciferase

Mingliang Yuan,† Xiaojie Ma,† Tianyu Jiang,‡ Yuqi Gao,‡ Yuanyuan Cui,‡ Chaochao Zhang,‡ Xingye Yang,‡ Yun Huang,§ Lupei Du,§ Ilia Yampolsky,¶,§ and Minyong Li,†,*,‡

†Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmacy, Shandong University, Jinan, Shandong 250012, China. Tel./fax: +86-531-8838-2076; E-mail: mli@sdu.edu.cn

‡Department of Otorhinolaryngology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China

§Centre for Epigenetics and Disease Prevention, Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, College of Medicine, Texas A&M University, Houston, TX 77030, USA

¶Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow 117997, Russia

§Pirogov Russian National Research Medical University, Ostrovitianov 1, Moscow 117997, Russia

¶State Key Laboratory of Microbial Technology, Shandong University, Jinan, Shandong 250100, China

† These authors contributed equally

CONTENT

1. Synthesis .............................................................................................................S-2
2. Stability evaluation in aqueous solution .............................................................S-5
3. Cytotoxicity Tests ................................................................................................S-7
4. Real-time imaging in cellulo and in vivo ............................................................S-8
5. ¹H NMR, ¹³C NMR and HR-MS spectra ............................................................S-9
1. Synthesis

**General Procedure 1**
Under argon the compound 1 (1 equiv.) was dissolved in anhydrous pyridine. The corresponding acid anhydride or acyl chloride was added (3-10 equiv.) and the reaction mixture stirred at 30 °C until starting material was consumed. The reaction mixture was firstly diluted with ethylacetate, and then washed three times with cold saturated copper sulfate solution. The extract was washed successively with brine solution and concentrated in vacuo. The crude product was purified by recrystallization from methanol.

**General Procedure 2**
Under argon, to a solution of a mixture containing compound 1 (1 equiv.), potassium carbonate (1 equiv.) and potassium iodide (1 equiv.) in anhydrous DMF was added chloromethylpivalate or other (5-10 equiv.). The mixture stirred at 30 °C until complete. Water was added and product was extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by recrystallization from methanol to afford the pure product.

**Compound 2:** The title compound 2 was synthesized from 1 (123 mg, 0.3 mmol, 1 equiv.) and acetic anhydride (85 μL, 0.9 mmol, 3 equiv.) according to General Procedure 1. Pale pink solid (76.5 mg, 56.5%); Mp.171-173 °C. $^1$H NMR (400 MHz, DMSO-$d_6$) δ 8.69 (s, 1H), 7.85 – 7.66 (m, 4H), 7.62 – 7.53 (m, 3H), 7.40 – 7.14 (m, 8H), 4.08 (s, 2H), 2.40 (s, 3H). $^{13}$C NMR (400 MHz, DMSO-$d_6$) δ 168.64 (1C), 150.62 (1C), 138.93 (1C), 137.36 (1C), 136.27 (2C), 136.10 (1C), 134.96 (1C), 131.30 (1C), 130.02 (1C), 129.68 (2C), 129.63 (2C), 129.32 (1C), 129.01 (2C), 128.96 (2C), 128.85 (1C), 127.41 (1C), 126.74 (2C), 126.09 (1C), 109.72 (1C), 32.87 (1C), 20.83 (1C). ESI-HRMS calcd.: 451.1354, found: 452.1433 (M+H$^+$).

**Compound 3:** The title compound 3 was synthesized from 1 (123 mg, 0.3 mmol, 1 equiv.) and isobutyryl chloride (155 μL, 1.5 mmol, 5 equiv.) according to General Procedure 1. Pale pink solid (64.8 mg, 45.1%); Mp.104-106 °C. $^1$H NMR (400 MHz, DMSO-$d_6$) δ 8.57 (s, 1H), 7.73 (td, J = 7.9, 3.0 Hz, 4H), 7.61 – 7.54 (m, 3H), 7.39 – 7.28 (m, 5H), 7.23 (dd, J = 15.7, 7.2 Hz, 3H), 4.04 (s, 2H), 3.09 – 3.00 (m, 1H), 1.27 (d, J = 7.0 Hz, 6H). $^{13}$C NMR (400 MHz, DMSO-$d_6$) δ 175.28 (1C), 139.71 (1C), 138.26 (1C), 137.13 (2C), 136.92 (1C), 135.62 (1C), 134.96 (1C), 131.30 (1C), 130.49 (2C), 130.45 (1C), 129.92 (2C), 129.84 (1C), 129.79 (2C), 129.69 (3C), 128.14 (1C), 127.57 (1C), 126.93 (2C), 110.25 (1C), 33.69 (1C), 33.14 (1C), 18.89 (2C). ESI-HRMS calcd.: 479.1667, found: 480.1743 (M+H$^+$).

**Compound 4:** The title compound 4 was synthesized from 1 (123 mg, 0.3 mmol, 1 equiv.) and cyclohexanecarboxylic acid chloride (120 μL, 0.9 mmol, 3 equiv) according to General Procedure 1. Pale pink solid (106.1 mg, 68.1%); Mp.95-97 °C. $^1$H NMR (400 MHz, DMSO-$d_6$) δ 8.53 (s, 1H), 7.81 – 7.67 (m, 4H), 7.61 – 7.51 (m, 3H),
7.41 – 7.29 (m, 5H), 7.29 – 7.14 (m, 3H), 4.03 (s, 2H), 2.85 (tt, $J = 10.8, 3.6$ Hz, 1H), 2.11 – 1.95 (m, 2H), 1.79 – 1.70 (m, 2H), 1.64 (dd, $J = 8.3, 3.8$ Hz, 1H), 1.56 – 1.44 (m, 2H), 1.42 – 1.31 (m, 2H), 1.22 (dd, $J = 16.3, 6.9$ Hz, 1H).$^{13}$C NMR (400 MHz, DMSO-$d_6$) δ 173.01 (1C), 150.70 (1C), 138.85 (1C), 137.45 (1C), 136.27 (2C), 136.10 (1C), 134.76 (1C), 131.33 (1C), 130.03 (1C), 129.68 (1C), 129.65 (1C), 129.13 (2C), 129.03 (2C), 128.99 (2C), 128.89 (2C), 127.41 (1C), 126.78 (1C), 126.16 (2C), 109.54 (1C), 41.99 (1C), 32.91 (1C), 28.57 (2C), 25.63 (1C), 25.16 (2C). ESI-HRMS calcd.: 519.1980, found: 520.2063 (M+H$^+$).

Compound 5: The title compound 5 was synthesized from 1 (150 mg, 0.367 mmol, 1 equiv.) and trimethylacetyl chloride (225 μL, 1.83 mmol, 5 equiv.) according to General Procedure 1. Pale pink solid (143 mg, 79.0%); Mp. 155-157°C. $^1$H NMR (400 MHz, DMSO-$d_6$) δ 8.26 (s, 1H), 7.81 – 7.68 (m, 4H), 7.63 – 7.53 (m, 3H), 7.40 – 7.28 (m, 5H), 7.23 (dd, $J = 14.6, 7.2$ Hz, 3H), 4.04 (s, 2H), 1.37 (s, 8H).$^{13}$C NMR (400 MHz, DMSO-$d_6$) δ 176.82 (1C), 151.75 (1C), 139.65 (1C), 138.36 (1C), 137.12 (2C), 136.86 (1C), 135.63 (1C), 132.14 (1C), 130.85 (1C), 130.49 (2C), 130.45 (1C), 129.87 (4C), 129.83 (1C), 129.70 (2C), 128.12 (1C), 127.59 (1C), 127.04 (2C), 109.77 (1C), 39.69 (1C), 33.18 (1C), 27.20 (3C). ESI-HRMS calcd.: 493.1824, found: 494.1897 (M+H$^+$).

Compound 6: The title compound 6 was synthesized from 1 (123 mg, 0.3 mmol, 1 equiv.) and 1-adamantanecarbonyl chloride (357.6 mg, 1.8 mmol, 6 equiv.) according to General Procedure 1. Pale pink solid (103 mg, 60.3%); Mp. 148-150°C. $^1$H NMR (400 MHz, DMSO-$d_6$) δ 8.20 (s, 1H), 7.68 (dd, $J = 6.7, 1.5$ Hz, 4H), 7.54 – 7.49 (m, 3H), 7.34 – 7.24 (m, 5H), 7.19 (dd, $J = 11.8, 7.1$ Hz, 3H), 3.98 (s, 2H), 2.02 (s, 9H), 1.70 (s, 6H). $^{13}$C NMR (400 MHz, DMSO-$d_6$) δ 173.33 (1C), 150.83 (1C), 138.79 (1C), 137.53 (1C), 136.27 (2C), 136.03 (1C), 134.78 (1C), 131.38 (1C), 130.04 (1C), 129.68 (2C), 129.64 (1C), 129.13 (2C), 129.06 (1C), 129.03 (2C), 128.91 (2C), 128.37 (1C), 126.80 (1C), 126.27 (2C), 109.03 (1C), 49.07 (1C), 42.06 (1C), 41.25 (1C), 38.11 (2C), 36.11 (2C), 32.94 (1C), 27.49 (2C). ESI-HRMS calcd.: 571.2293, found: 572.2275 (M+H$^+$).

Compound 7: The title compound 7 was synthesized from 1 (150 mg, 0.367 mmol, 1 equiv.) and chloromethyl butyrate (382 μL, 3 mmol, 8 equiv.) according to General Procedure 2. Yellow viscous powder (86.4 mg, 46.2%); Mp. 97-99°C. $^1$H NMR (400 MHz, DMSO-$d_6$) δ 8.62 (s, 1H), 7.77 (dd, $J = 8.0, 1.5$ Hz, 2H), 7.72 – 7.68 (m, 2H), 7.56 (dd, $J = 5.0, 1.8$ Hz, 3H), 7.36 – 7.30 (m, 7H), 7.26 – 7.20 (m, 1H), 5.79 (s, 2H), 4.11 (s, 2H), 2.26 (t, $J = 7.3$ Hz, 2H), 1.52 – 1.38 (m, 2H), 0.76 (t, $J = 7.4$ Hz, 3H). $^{13}$C NMR (400 MHz, DMSO-$d_6$) δ 173.12 (1C), 151.08 (1C), 140.39 (1C), 138.00 (1C), 137.06 (2C), 136.75 (1C), 134.45 (1C), 131.28 (1C), 130.76 (1C), 130.45 (2C), 130.06 (1C), 129.87 (2C), 129.80 (2C), 129.70 (1C), 129.62 (2C), 128.32 (1C), 127.44 (1C), 126.74 (2C), 110.12 (1C), 90.37 (1C), 35.66 (1C), 32.58 (1C), 17.98 (1C), 13.73 (1C). ESI-HRMS calcd.: 509.1773, found: 510.1854 (M+H$^+$), 532.1666(M+Na$^+$).

Compound 8: The title compound 8 was synthesized from 1 (123 mg, 0.3 mmol, 1 equiv.) and chloromethyl pivalate (382 μL, 3 mmol, 10 equiv.) according to General
Procedure 2. Pale pink solid (76.5 mg, 48.7%); Mp.93-95 °C.\(^1\)H NMR (400 MHz, DMSO-\(d_6\)) \(\delta\) 8.57 (s, 1H), 7.76 (dd, \(J = 8.0, 1.5\) Hz, 2H), 7.73 – 7.66 (m, 2H), 7.59 – 7.51 (m, 3H), 7.38 – 7.28 (m, 7H), 7.26 – 7.18 (m, 1H), 5.83 (s, 2H), 4.15 (s, 2H), 1.08 (s, 9H).\(^{13}\)C NMR (400 MHz, DMSO-\(d_6\)) \(\delta\) 178.11 (1C), 151.49 (1C), 140.34 (1C), 137.95 (1C), 137.04 (2C), 137.01 (1C), 136.89 (1C), 134.20 (1C), 131.21 (1C), 130.75 (1C), 130.44 (2C), 129.88 (2C), 129.80 (2C), 129.71 (1C), 129.65 (2C), 128.30 (1C), 127.47 (1C), 126.70 (2C), 110.08 (1C), 91.25 (1C), 38.90 (1C), 32.72 (1C), 27.11 (3C). ESI-HRMS calcd.: 523.1930, found: 524.2000 (M+H\(^+\)).

Compound 9: The title compound 9 was synthesized from 1 (123 mg, 0.3 mmol, 1 equiv.) and diethy pyrocarbonate (434 \(\mu\)L, 3 mmol, 10 equiv.) according to General Procedure 1. Pale pink solid (53.4 mg, 37.0%); Mp.150-152 °C.\(^1\)H NMR (400 MHz, DMSO-\(d_6\)) \(\delta\) 8.83 (s, 1H), 7.78 (dd, \(J = 6.4, 2.9\) Hz, 2H), 7.72 (dd, \(J = 6.4, 2.9\) Hz, 2H), 7.58-7.54 (m, 3H), 7.38 – 7.19 (m, 8H), 4.29 (q, \(J = 7.1\) Hz, 2H), 4.10 (s, 1H), 1.31 (t, \(J = 7.1\) Hz, 3H).\(^{13}\)C NMR (400 MHz, DMSO-\(d_6\)) \(\delta\) 151.35 (1C), 150.69 (1C), 138.65 (1C), 137.51 (1C), 136.28 (2C), 136.07 (1C), 134.75 (1C), 131.04 (1C), 130.06 (1C), 129.94 (1C), 129.71 (2C), 129.22 (2C), 129.04 (1C), 128.97 (2C), 128.89 (2C), 127.36 (1C), 126.81 (1C), 126.17 (2C), 109.95 (1C), 66.83 (1C), 32.98 (1C), 14.25 (1C). ESI-HRMS calcd.: 481.1640, found: 482.1588 (M+H\(^+\)).

Compound 10: The title compound 10 was synthesized from 1 (123 mg, 0.3 mmol, 1 equiv.) and di-tert-butyl dicarbonate (740 \(\mu\)L, 3 mmol, 10 equiv.) according to General Procedure 1. Pale pink solid (50.4 mg, 33.0%); Mp:135-137 °C.\(^1\)H NMR (400 MHz, DMSO-\(d_6\)) \(\delta\) 8.74 (s, 1H), 7.79 (d, \(J = 7.8\) Hz, 2H), 7.72 (dd, \(J = 5.8, 2.4\) Hz, 2H), 7.57 (d, \(J = 5.0\) Hz, 3H), 7.39 – 7.20 (m, 8H), 4.08 (s, 2H), 1.49 (s, 9H).\(^{13}\)C NMR (400 MHz, DMSO-\(d_6\)) \(\delta\) 151.58 (1C), 150.33 (1C), 139.61 (1C), 138.29 (1C), 137.08 (2C), 136.91 (1C), 136.28 (2C), 136.07 (1C), 134.75 (1C), 131.04 (1C), 130.06 (1C), 129.94 (1C), 129.71 (2C), 129.22 (2C), 129.04 (1C), 128.97 (2C), 128.89 (2C), 127.36 (1C), 126.81 (1C), 126.17 (2C), 109.95 (1C), 66.83 (1C), 32.98 (1C), 14.25 (1C). ESI-HRMS calcd.: 509.1773, found: 510.1842 (M+H\(^+\)).

Compound 11: The title compound 11 was synthesized from 1 (123 mg, 0.3 mmol, 1 equiv.) and chloromethyl isopropyl carbonate (398.8 \(\mu\)L, 3 mmol, 10 equiv.) according to General Procedure 2. Pale pink solid (77.7 mg, 49.3%); Mp.105-107 °C.\(^1\)H NMR (400 MHz, DMSO-\(d_6\)) \(\delta\) 8.58 (s, 1H), 7.75 (d, \(J = 8.0\) Hz, 2H), 7.70 (dd, \(J = 6.4, 2.8\) Hz, 2H), 7.58 – 7.54 (m, 3H), 7.35-7.31 (m, 7H), 7.22 (tt, \(J = 8.3, 4.0\) Hz, 1H), 5.78 (s, 2H), 4.81-4.75 (m,1H), 4.09 (s, 2H), 3.17 (d, \(J = 5.2\) Hz, 2H), 1.15 (d, \(J = 6.2\) Hz, 6H).\(^{13}\)C NMR (400 MHz, DMSO-\(d_6\)) \(\delta\) 154.34 (1C), 151.51 (1C), 140.19 (1C), 138.06 (1C), 137.07 (2C), 136.47 (1C), 134.73 (1C), 131.27 (1C), 130.80 (1C), 130.47 (2C), 129.94 (2C), 129.81 (2C), 129.75 (1C), 129.64 (2C), 128.24 (1C), 127.48 (1C), 126.76 (2C), 110.14 (1C), 93.30 (1C), 73.80 (1C), 49.37 (1C), 32.64 (1C), 21.80 (2C). ESI-HRMS calcd.:525.1722, found: 526.1799 (M+H\(^+\)).

acetyl-BDC: The title compound acetyl-BDC was synthesized from 1 (50mg, 0.11 mmol, equiv) acetic anhydride (118mg, 1.1 mmol, 10 equiv.) according to General
Procedure 1. Yellow oil (15 mg, 27.3%); Purity 95.27%; 1H NMR (400 MHz, DMSO-d$_6$) δ 7.87 (d, J = 7.4 Hz, 2H), 7.77 (s, 1H), 7.61 (d, J = 7.4 Hz, 2H), 7.51 – 7.18 (m, 11H), 4.61 (s, 2H), 4.20 (s, 2H), 2.15 (s, 3H). ESI-HRMS calcd.: 433.1790, found: [M+H]$^+$ 434.1862.

2. Stability evaluation in aqueous solution

Figure S1. In vitro stability study of the luciferin esters (UV): (A) differential absorption spectroscopy (compound 2); (B) absorbance data analysis at 270 nm (compound 2); (C) absorbance data analysis at 358 nm (compound 2); (D) differential absorption spectroscopy (compound 10); (E) absorbance data analysis at 270 nm (compound 10); (F) absorbance data analysis at 358 nm (compound 10).
**Figure S2.** *In vitro* stability study of the luciferin esters (HPLC): (A) HPLC analysis over time (compound 3); (B) HPLC dynamics data analysis for the first 6 hours (compound 3); (C) HPLC analysis over time (compound 4); (D) HPLC dynamics data analysis for the first 6 hours (compound 4); (E) HPLC analysis over time (compound 5); (F) HPLC dynamics data analysis for the first 6 hours (compound 5); (G) HPLC analysis over time (compound 6); (H) HPLC dynamics data analysis for the first 6 hours (compound 6); (I) HPLC analysis over time (compound 7); (J) HPLC dynamics data analysis for the first 6 hours (compound 7); (K) HPLC analysis over time (compound 8); (L) HPLC dynamics data analysis for the first 6 hours (compound 8); (M) HPLC analysis over time (compound 9); (N) HPLC dynamics data analysis for the first 6 hours (compound 9); (O) HPLC analysis over time (compound 11); (P) HPLC dynamics data analysis for the first 6 hours (compound 11);

### 3. Cytotoxicity Tests

**Table S1.** Cytotoxicity of the luciferin esters.

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC$_{50}$ (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>190.5 ± 6.12</td>
</tr>
<tr>
<td>3</td>
<td>542.4 ± 11.50</td>
</tr>
<tr>
<td>4</td>
<td>&gt; 1000</td>
</tr>
<tr>
<td>5</td>
<td>&gt; 1000</td>
</tr>
<tr>
<td>6</td>
<td>782.6 ± 16.67</td>
</tr>
<tr>
<td>7</td>
<td>381.6 ± 9.36</td>
</tr>
<tr>
<td>8</td>
<td>&gt; 1000</td>
</tr>
<tr>
<td>9</td>
<td>579.6 ± 13.12</td>
</tr>
<tr>
<td>10</td>
<td>516.1 ± 9.57</td>
</tr>
</tbody>
</table>
4. Real-time imaging *in cellulo* and *in vivo*

**Figure S3.** ES-2-Rluc cell imaging: the bioluminescence intensity of the luciferin esters in the cells over time.

**Figure S4.** The bioluminescence intensity of the free luciferin and the luciferin esters *in vivo* over time.
5. $^1$H NMR, $^{13}$C NMR and HR-MS spectra

Compound 2:
Compoud 3:
Compound 4:
Compoud 5:
Compoud 6:
Compound 7:
Compound 8:
Compoud 9:
Compoud 10:
Compound 11: